Home » Padcev and Keytruda Combination Approved for Urothelial Cancer
Padcev and Keytruda Combination Approved for Urothelial Cancer
The FDA has granted Accelerated Approval to Astellas Pharma and Seagen’s Padcev (enfortumab vedotin-ejfv) in combination with Merck’s Keytruda (pembrolizumab) for treatment of adults with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.
The agency decision was based on trial results that showed a durable tumor response. In one clinical study, the combination therapy showed a response rate of 68 percent, with a complete response in 12 percent of participants.
A full approval for the indication will depend on a verification of the clinical benefit in a confirmatory trial.
Related Topics
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct